Morgan Stanley’s Ariad Pharmaceuticals Inc ARIA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-1,076,629
| Closed | -$13.4M | – | 6730 |
|
|
2016
Q4 | $13.4M | Sell |
1,076,629
-401,704
| -27% | -$4.84M | ﹤0.01% | 1940 |
|
|
2016
Q3 | $20.2M | Buy |
1,478,333
+666,217
| +82% | +$6.69M | 0.01% | 1441 |
|
|
2016
Q2 | $6M | Buy |
812,116
+545,817
| +205% | +$4.1M | ﹤0.01% | 2436 |
|
|
2016
Q1 | $1.7M | Buy |
266,299
+28,222
| +12% | +$158K | ﹤0.01% | 3478 |
|
|
2015
Q4 | $1.49M | Sell |
238,077
-49,769
| -17% | -$327K | ﹤0.01% | 3744 |
|
|
2015
Q3 | $1.68M | Sell |
287,846
-298,908
| -51% | -$2.3M | ﹤0.01% | 3678 |
|
|
2015
Q2 | $4.85M | Buy |
586,754
+201,438
| +52% | +$1.78M | ﹤0.01% | 2821 |
|
|
2015
Q1 | $3.18M | Sell |
385,316
-83,733
| -18% | -$619K | ﹤0.01% | 3157 |
|
|
2014
Q4 | $3.22M | Buy |
469,049
+32,450
| +7% | +$203K | ﹤0.01% | 3143 |
|
|
2014
Q3 | $2.36M | Sell |
436,599
-970,171
| -69% | -$5.67M | ﹤0.01% | 3294 |
|
|
2014
Q2 | $8.96M | Buy |
1,406,770
+822,432
| +141% | +$5.66M | ﹤0.01% | 2138 |
|
|
2014
Q1 | $4.71M | Buy |
584,338
+237,559
| +69% | +$1.85M | ﹤0.01% | 2637 |
|
|
2013
Q4 | $2.37M | Sell |
346,779
-666,737
| -66% | -$3.6M | ﹤0.01% | 3258 |
|
|
2013
Q3 | $18.6M | Buy |
1,013,516
+435,511
| +75% | +$8.46M | 0.01% | 1279 |
|
|
2013
Q2 | $10.1M | Buy |
+578,005
| New | +$10.2M | 0.01% | 1699 |
|
Other funds holding ARIA
Morgan Stanley's ARIA Position: Q1 2017 in Review
Morgan Stanley sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 1,076,629 shares — an estimated $13.4M sold.
Morgan Stanley first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $20.2M in Q3 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.
- Morgan Stanley reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
- Morgan Stanley sold 1,076,629 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $13.4M.
- Morgan Stanley first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- Morgan Stanley's Ariad Pharmaceuticals Inc position peaked at $20.2M in Q3 2016.
- 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.
Based on Morgan Stanley's 13F filing for Q1 2017, filed 12 May 2017.